Cargando…

Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice

BACKGROUND AND AIM: The morbidity and mortality of Shigella infections remain a global challenge. Epitope-based vaccine development is an emerging strategy to prevent bacterial invasion. This study aimed to identify the ability of the 49.8 kDa pili subunit adhesin protein epitope of Shigella flexner...

Descripción completa

Detalles Bibliográficos
Autores principales: Anam, Khoirul, Endharti, Agustina Tri, Poeranto, Sri, Sujuti, Hidayat, Hidayati, Dwi Yuni Nur, Prawiro, Sumarno Reto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Veterinary World 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980390/
https://www.ncbi.nlm.nih.gov/pubmed/35400957
http://dx.doi.org/10.14202/vetworld.2022.281-287
_version_ 1784681381785239552
author Anam, Khoirul
Endharti, Agustina Tri
Poeranto, Sri
Sujuti, Hidayat
Hidayati, Dwi Yuni Nur
Prawiro, Sumarno Reto
author_facet Anam, Khoirul
Endharti, Agustina Tri
Poeranto, Sri
Sujuti, Hidayat
Hidayati, Dwi Yuni Nur
Prawiro, Sumarno Reto
author_sort Anam, Khoirul
collection PubMed
description BACKGROUND AND AIM: The morbidity and mortality of Shigella infections remain a global challenge. Epitope-based vaccine development is an emerging strategy to prevent bacterial invasion. This study aimed to identify the ability of the 49.8 kDa pili subunit adhesin protein epitope of Shigella flexneri to induce an intestinal immune response in mice. MATERIALS AND METHODS: Thirty adult male Balb/c mice were divided into a control group, cholera toxin B subunit (CTB) group, CTB+QSSTGTNSQSDLDS (pep_1) group, CTB+DTTITKAETKTVTKNQVVDTPVTTDAAK (pep_2) group, and CTB+ ATLGATLNRLDFNVNNK (pep_3). We performed immunization by orally administering 50 μg of antigen and 50 μl of adjuvant once a week over 4 weeks. We assessed the cellular immune response by quantifying T helper 2 (Th2) and Th17 using flow cytometry. In addition, we assessed the humoral immune response by quantifying interleukin (IL-4), IL-17, secretory immunoglobulin A (sIgA), and β-defensin using enzyme-linked immunoassay. Statistical analysis was performed using one-way analysis of variance and Kruskal–Wallis test. RESULTS: Peptide oral immunization increases the cellular immune response as reflected by the increase of Th2 (p=0.019) and Th17 (p=0.004) cell counts, particularly in the CTB_pep_1 group. Humoral immune response activation was demonstrated by increased IL-4 levels, especially in the CTB+pep_3 group (p=0.000). The IL-17 level was increased significantly in the CTB+pep_1 group (p=0.042). The mucosal immune response was demonstrated by the sIgA levels increase in the CTB+pep_3 group (p=0.042) and the β-defensin protein levels (p=0.000). CONCLUSION: All selected peptides activated the cellular and humoral immune responses in the intestine of mice. Further studies are necessary to optimize antigen delivery and evaluate whether the neutralizing properties of these peptides allow them to prevent bacterial infection.
format Online
Article
Text
id pubmed-8980390
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Veterinary World
record_format MEDLINE/PubMed
spelling pubmed-89803902022-04-08 Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice Anam, Khoirul Endharti, Agustina Tri Poeranto, Sri Sujuti, Hidayat Hidayati, Dwi Yuni Nur Prawiro, Sumarno Reto Vet World Research Article BACKGROUND AND AIM: The morbidity and mortality of Shigella infections remain a global challenge. Epitope-based vaccine development is an emerging strategy to prevent bacterial invasion. This study aimed to identify the ability of the 49.8 kDa pili subunit adhesin protein epitope of Shigella flexneri to induce an intestinal immune response in mice. MATERIALS AND METHODS: Thirty adult male Balb/c mice were divided into a control group, cholera toxin B subunit (CTB) group, CTB+QSSTGTNSQSDLDS (pep_1) group, CTB+DTTITKAETKTVTKNQVVDTPVTTDAAK (pep_2) group, and CTB+ ATLGATLNRLDFNVNNK (pep_3). We performed immunization by orally administering 50 μg of antigen and 50 μl of adjuvant once a week over 4 weeks. We assessed the cellular immune response by quantifying T helper 2 (Th2) and Th17 using flow cytometry. In addition, we assessed the humoral immune response by quantifying interleukin (IL-4), IL-17, secretory immunoglobulin A (sIgA), and β-defensin using enzyme-linked immunoassay. Statistical analysis was performed using one-way analysis of variance and Kruskal–Wallis test. RESULTS: Peptide oral immunization increases the cellular immune response as reflected by the increase of Th2 (p=0.019) and Th17 (p=0.004) cell counts, particularly in the CTB_pep_1 group. Humoral immune response activation was demonstrated by increased IL-4 levels, especially in the CTB+pep_3 group (p=0.000). The IL-17 level was increased significantly in the CTB+pep_1 group (p=0.042). The mucosal immune response was demonstrated by the sIgA levels increase in the CTB+pep_3 group (p=0.042) and the β-defensin protein levels (p=0.000). CONCLUSION: All selected peptides activated the cellular and humoral immune responses in the intestine of mice. Further studies are necessary to optimize antigen delivery and evaluate whether the neutralizing properties of these peptides allow them to prevent bacterial infection. Veterinary World 2022-02 2022-02-11 /pmc/articles/PMC8980390/ /pubmed/35400957 http://dx.doi.org/10.14202/vetworld.2022.281-287 Text en Copyright: © Anam, et al. https://creativecommons.org/licenses/by/4.0/Open Access. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Anam, Khoirul
Endharti, Agustina Tri
Poeranto, Sri
Sujuti, Hidayat
Hidayati, Dwi Yuni Nur
Prawiro, Sumarno Reto
Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice
title Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice
title_full Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice
title_fullStr Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice
title_full_unstemmed Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice
title_short Shigella flexneri vaccine development: Oral administration of peptides derived from the 49.8 kDa pili protein subunit activates the intestinal immune response in mice
title_sort shigella flexneri vaccine development: oral administration of peptides derived from the 49.8 kda pili protein subunit activates the intestinal immune response in mice
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980390/
https://www.ncbi.nlm.nih.gov/pubmed/35400957
http://dx.doi.org/10.14202/vetworld.2022.281-287
work_keys_str_mv AT anamkhoirul shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice
AT endhartiagustinatri shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice
AT poerantosri shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice
AT sujutihidayat shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice
AT hidayatidwiyuninur shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice
AT prawirosumarnoreto shigellaflexnerivaccinedevelopmentoraladministrationofpeptidesderivedfromthe498kdapiliproteinsubunitactivatestheintestinalimmuneresponseinmice